Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More
Xconomy
AUGUST 26, 2016
—Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. A Phase 2 trial of the drug, AMX0035, should start in late 2016 or early 2017.
Let's personalize your content